Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer

Author(s): Ian S. Dayes, MD, MSc^1,2,3,4; Ur Metser, MD^5,6; Nicole Hodgson, MD, MSc⁷; Sameer Parpia, PhD^1,3,4; Andrea F. Eisen, MD^8,9,10; Ralph George, MD^11,12; Phillip Blanchette, MD, MSc^13,14; Tulin D. Cil, MD^6,11; Angel Arnaout, MD^15,16; Adrien Chan, MD, MPH^17,18; and Mark N. Levine, MD, MSc^1,2,3,4

Source: DOI: 10.1200/JCO.23.00249 Journal of Clinical Oncology 41, no. 23 (August 10, 2023) 3909-3916.

Dr. Maen Hussein's Thoughts

It seems that PET is better than CT scan in locally advanced disease staging, better in upstaging, and may spare the patient combined modality therapy.

PURPOSE

Patients with locally advanced breast cancer (LABC) typically undergo staging tests at presentation. If staging does not detect metastases, treatment consists of curative intent combined modality therapy (neoadjuvant chemotherapy, surgery, and regional radiation). Positron emission tomography-computed tomography (PET-CT) may detect more asymptomatic distant metastases, but the evidence is based on uncontrolled studies.

METHODS

For inclusion, patients had histological evidence of invasive ductal carcinoma of the breast and TNM stage III or IIb (T3N0, but not T2N1). Consenting patients from six regional cancer centers in Ontario were randomly assigned to 18F-labeled fluorodeoxyglucose PET-CT or conventional staging (bone scan, CT of the chest/abdomen and pelvis). The primary end point was upstaging to stage IV. A key secondary outcome was receiving curative intent combined modality therapy (ClinicalTrials.gov identifier: NCT02751710).

RESULTS

Between December 2016 and April 2022, 184 patients were randomly assigned to whole-body PET-CT and 185 patients to conventional staging. Forty-three (23%) PET-CT patients were upstaged to stage IV compared with 21 (11%) conventional staged patients (absolute difference, 12.3% [95% CI, 3.9 to 19.9]; P = .002). Consequently, treatment was changed in 35 (81.3%) of 43 upstaged PET-CT patients and 20 (95.2%) of the 21 upstaged conventional patients. Subsequently, 149 (81%) patients in the PET-CT group received combined modality treatment versus 165 (89.2%) patients in the conventional staging group (absolute difference, 8.2% [95% CI, 0.1 to 15.4]; P = .03).

CONCLUSION

In patients with LABC, PET-CT detected more distant metastases than conventional staging, and fewer PET-CT patients received combined modality therapy. Our randomized trial demonstrates the utility of the PET-CT staging strategy.

Author Affiliations

¹Department of Oncology, McMaster University, Hamilton, ON, Canada;²Juravinski Cancer Centre—Hamilton Health Sciences, Hamilton, ON, Canada;³Ontario Clinical Oncology Group, Hamilton, ON, Canada;⁴Escarpment Cancer Research Institute, Hamilton, ON, Canada;⁵Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada;⁶University Health Network Princess Margaret Cancer Centre, Toronto, ON, Canada;⁷Department of Surgery, McMaster University, Hamilton, ON, Canada;⁸Department of Medicine, University of Toronto, Toronto, ON, Canada;⁹Sunnybrook Health Sciences Centre—Odette Cancer Centre, Toronto, ON, Canada;¹⁰Ontario Health, Toronto, ON, Canada;¹¹Department of Surgery, University of Toronto, Toronto, ON, Canada;¹²St Michael’s Hospital, Toronto, ON, Canada;¹³Department of Oncology, Western University, London, ON, Canada;¹⁴London Health Sciences Regional Cancer Program, London, ON, Canada;¹⁵Department of Surgery, Ottawa University, Ottawa, ON, Canada;¹⁶Ottawa Hospital Cancer Centre, Ottawa, ON, Canada;¹⁷Northern Ontario School of Medicine, Thunder Bay ON, Canada;¹⁸Thunder Bay Regional Health Sciences Cancer Centre, Thunder Bay, ON, Canada

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis

Among 1,545 women included with a median follow-up of 9.4 years in postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls HR, 0.51, with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed dose was 5mg daily of 10mg every other day in ductal carcinoma in situ (DCIS) and high-risk pts. Less is as good.

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

644 patients who are triple-negative breast cancer (TNBC) not candidates for immunotherapy were randomly assigned to receive Dato-DXd (n = 323) or chemotherapy (n = 321). Median progression-free survival (PFS) was 10.8 months with Dato-DXd and 5.6 months with chemotherapy. Median overall survival (OS) was 23.7 months and 18.7 months with Dato-DXd and chemotherapy, respectively HR 0.79; P = 0.029]. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in 105 (33%) and 89 (29%) patients who received Dato-DXd and chemotherapy, respectively, they were more treatment discontinuation in the chemotherapy arm secondary to treatment related adverse events in 14 (4%) and 23 (7%) patients. There were no treatment-related deaths in either arm. New standard of care? Recall this is on patients not eligible for immunotherapy.

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

Less radiation (40Gy vs 50 Gy) was non inferior in preventing locoregional recurrence and distant mets, also lymphedema rates were not worse. Would love feedback from our rad onc, but it seems less is as good.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Progression-free survival (PFS) was statistically significantly improved with addition of tucatinib versus placebo 24.9 v 16.3 months regardless of the presence/absence of BM or hormone receptor status.

Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.

1467 pts with RS > 25 and 551 with clinically (neoadjuvant cohort in ADAPT-HR+/HER2-) or pathologically N2, (longer) docetaxel-based CTx showed better distant, invasive disease-free survival in N2-3 pts patients with RS ≤25, OS was also shown in pts with RS>25 anthracycline regimens did not show a significant survival difference in high-risk HR+/HER2 whether used in neoadjuvant or adjuvant setting. So may be no anthracycline for HR+ve pts who are high risk disease.